# A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

> **NCT05756153** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genfleet Therapeutics (Shanghai) Inc.** · enrollment: 47 (actual)

## Conditions studied

- Advance Non-small Cell Lung Cancer

## Interventions

- **DRUG:** GFH925
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05756153
- **Lead sponsor:** Genfleet Therapeutics (Shanghai) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2025-04-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2025-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05756153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05756153, "A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05756153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*